Salud financiera de hoja de balance de Poolbeg Pharma

Salud financiera controles de criterios 6/6

Poolbeg Pharma tiene un patrimonio de los accionistas total de £12.4M y una deuda total de £0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son £13.0M y £561.0K respectivamente.

Información clave

Ratio deuda-patrimonio

UK£0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	UK£10.06m
Patrimonio	UK£12.45m
Total pasivo	UK£561.00k
Activos totales	UK£13.01m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12

Recent updates

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Aug 20

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Feb 16

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Oct 05

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Jun 01

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (£11.0M) de POLB superan a sus pasivos a corto plazo (£561.0K).

Pasivo a largo plazo: POLB no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: POLB está libre de deudas.

Reducción de la deuda: POLB no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: POLB tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: POLB dispone de suficiente cash runway para 1.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 10.4% cada año.

Salud financiera de hoja de balance de Poolbeg Pharma

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Recent updates

Poolbeg Pharma plc Announces U.S. Patent Office Grants U.S. Immunomodulator I Patent

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

New minor risk - Financial data availability

Executive Chairman of The Board recently bought UK£97k worth of stock

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

New minor risk - Share price stability

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Less than half of directors are independent

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

No independent directors

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Poolbeg Pharma PLC has completed an IPO in the amount of £25 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera